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Abstract
Canine malignant melanoma (CMM) is the most common canine oral tumour, and up to 70–75% ofAQ2
dogs in stage II–III die within 1 year after surgery. The purpose of this study was to evaluate the
expression of platelet-derived growth factors receptors (PDGFR)-𝛼 and -𝛽 in stage II and III CMMs and
to correlate it with prognosis. PDGFRs expression was evaluated by immunohistochemistry on 48
cases of formalin-fixed CMM samples and correlated with clinical–pathological findings and outcome
after surgery. PDGFRs co-expression was observed in 37.5% of cases. Positivity for PDGFR-𝛼 and -𝛽
receptor was present in 54.2 and 47.9% of cases, respectively. Ki67 values >19.5% were ascertained in
66.7% of cases. Statistical analysis showed that PDGFRs co-expression and Ki67 values> 19.5% were
both associated with worse prognosis. PDGFRs expression suggests a role in the pathogenesis and
progression of CMM, and 𝛼 and 𝛽 co-expression appears to be associated to worse prognosis.
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Introduction
Malignant melanoma (MM) represents the most
frequent oral neoplasm occurring in dogs.1–3 Oral
canine MM (CMM) has an aggressive behaviour,
grows rapidly, is locally invasive, frequently metas-
tasizes to regional lymph nodes (RLNs) and distant
sites, and it may recur following surgical resection.
Nuclear atypia, mitotic index and Ki67 index are
the prognostic factors that are known to be most
significant.4 The molecular alterations involved in
CMM arising from mucosal or digital sites have
not been yet fully identified. Recently, Gillard
et al.5 used cDNA sequencing data from 95 dogs
to detect somatic mutations in NRAS and PTEN
genes at human hotspot sites, while no mutations
were found in the analysis of BRAF Exon 15,6 as
frequently occurs in human melanomas.7,8
Platelet-derived growth factors recep-
tors (PDGFR-𝛼 and PDGFR-𝛽) are tyrosine
kinases receptors that can activate many of the
major signal transduction pathways, including
phosphatidylinositol 3-kinase (PI3K), Ras,
mitogen-activated protein kinase (MAPK) and
phospholipase C𝛾 pathways.7
They are involved in physiological and patholog-
ical diseases mainly by paracrine mechanisms. In
the physiological processes of adults, they stimulate
fibroblast and endothelial cell proliferation and
are involved in tissue regeneration and fibrotic
processes; during embryogenesis they are respon-
sible for tissue differentiation.8,9 In human cancers
PDGFRs can be activated by various genetic
alterations,10,11 and tumours of mesenchimal, glial
and haematopoietic origin may show PDGFRs
dysfunctions.12 The most frequent alterations are
over-expression, constitutive activation of the tyro-
sine kinase domain as well as post-transcriptional
regulation by specific RNA sequences such as
miRNA 34.13 The dysfunction of tyrosine kinases
occurs frequently in human cancers, and more
studies indicate that a similar pattern of dysfunc-
tion may also be observed in canine and feline
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cancers.14,15 In domestic animals PDGFRs have
been studied in canine osteosarcoma, lymphoma,
apocrine gland carcinoma, glioma and heman-
giosarcoma but their expression has not been
found to be correlated to prognosis.16–20
The aim of this research was to evaluate the
expression of PDGFR-𝛼 and -𝛽 in CMM, in order to
identify their role in the tumour pathogenesis and
their possible correlation with prognosis.
Materials andmethods
Sample collection and clinical follow-up
The tissue samples examined were from spon-
taneous oral CMMs, treated between 1998 and
February 2014 at the Department of Veterinary
Sciences of the University of Turin. In all cases,
the initial data collected included patient history,
physical examination, blood cell count, serum
biochemistry and urinalysis. Fine needle aspiration
of palpable RLNs, even if not enlarged (as size
has not been considered sufficiently predictive)21
and/or biopsy of the primary lesion were used for
preoperative tumour diagnosis. A definitive and
more objective staging was achieved in all cases
via the surgical removal of all palpable RLNs at
the time of primary tumour resection and their
full histological evaluation. Full tumour staging
included a skull and three-view chest radiographs
and abdominal ultrasound examination; alterna-
tively, a total body CT-scan was performed. Dogs
without concurrent life-threatening diseases but
with histologically confirmed stage II (2–4 cm
diameter, negative RLN) or III (>4 cm diame-
ter and negative RLN or any tumour size with
regional-positive surgically resected RLN)22 oral
CMM were included in the study. All the animals
were followed until the recurrence of the neoplasm,
death or for a minimum of 12months after surgery.
Together with the regional lymphadenectomy, a
primary tumour en bloc resection was performed,
with the inclusion, when feasible, of at least 2 cm of
macroscopically normal tissue around the tumour.
Histopathology
Formalin-fixed and paraffin-embedded sections
were subjected to haematoxylin/eosin staining
and histopathological examination was performed
by two independent pathologists (S. I.–L. M.),
recording mitotic index, degree of nuclear atypia
and amount of pigmentation.4,23,24 In order to
determine the melanocytic origin of the tumours,
each sample was tested for PNL-2 expression.2,4
Immunohistochemical analysis
Immunohistochemical (IHC) analysis was car-
ried out on 4 μm sections of formalin-fixed,
paraffin-embedded samples. Endogenous per-
oxidase activity was blocked with 3% hydrogen
peroxide in methanol for 30min at room tem-
perature. Sections underwent high-temperature
antigen unmasking by incubation at 98 ∘C with
citric acid buffer (pH 6.0). Samples were immuno-
histochemically tested for Ki67, PNL-2, PDGFR-𝛼
and 𝛽 expression. The details of primary antibodies
employed and the dilutions used are summarized
in Table 1. Antibodies were detected using the
avidin–biotin–peroxidase complex technique
with the Vectastain Elite ABC Kit (Vector Labo- AQ4
ratoires). The following external positive controls
were used: canine skin for PDGFR-𝛼 and canine
prostatic carcinoma for PDGFR-𝛽. As an internal
positive control, endothelial cells of the normal
blood vessels were used. For negative controls,
the sections were incubated in the absence of the
primary antibodies. Immunolabelled slides were
randomized and masked for blinded examina-
tion, which was performed independently by two
observers (L. M. and S. I.); in case of disagreement,
a consensus was reached using a multi-head micro-
scope. Cytoplasmic positivity was evaluated in
both tumour and stromal cells, located separately
using the scoring system adopted by Donnem et al.
(2008).25 Immunostaining at the stromal level was
Table 1. Source and conditions of the antibodies employed
Antibody Type Source IHC
PDGFR-𝛼 Rabbit polyclonal Santa Cruz
Biotechnology
1:200
AQ3
PDGFR-𝛽 Rabbit polyclonal Santa Cruz
Biotechnology
1:200
Ki67 Rabbit polyclonal Dako 1:25
PNL-2 Rabbit polyclonal Santa Cruz
Biotechnology
1:25
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considered as cytoplasmic labelling in the fibro-
connective tissue that forms bundles within and
surrounding the tumour.
Ki67 was evaluated considering the cut-off of
19.5 positive cells in five ×400 fields.24
Statistical analysis
IHC results and clinical–pathological findings were
grouped into contingency tables and analysed using
Pearson’s Chi-squared test with Yates’ continuity
correction. Survival curves were computed using
the Kaplan–Meier method and tests for differences
in survival, considering all known prognostic fac-
tors for CMM, were performed using the log-rank
test. Co-expression and presence of Ki67 values
greater than 19.5% were evaluated in interaction
using a Cox proportional hazard regression model.
Overall survival (OS) was considered as the num-
ber of days between surgery and death, while the
disease-free interval (DFI) as the number of days
between surgery and tumour recurrence and/or evi-
dence of metastasis. Cases that were still alive or
that did not present tumour recurrence or metasta-
sis at the end of the monitoring period (minimum
12months), or that died for unrelated causes, were
considered as censored. Data were analysed with
R (R Core Team (2014). R: R Foundation for Sta-
tistical Computing, Vienna, Austria); P values less
than 0.05 were considered statistically significant.
Results
Epidemiologic and clinical data
The data presented here come from 48 cases of oral
CMMs.Themean age of dogs was 11.4 years (range:
5–14 years); 64.6% of the dogs (31/48) were males
and 35.4% (17/48) females. Fifty percent of dogs
were mixed breed, while 50% were pure breeds.
The latter included: five dachshunds (10.4%), four
Cockers (8.3%), three German Shepherds (6.3%),
three Golden Retrievers (6.3%) and one each of
(2.1%) SyberianHusky, Beagle,Dogue deBordeaux,
Greyhound, Yorkshire terrier, Schnauzer, Minia-
ture Schnauzer, West Highland White Terrier and
Labrador Retriever.
A total of 20 dogs had a stage II oral CMM
and 28 a stage III oral CMM. All dogs underwent
surgical excision. Histology revealed incomplete
excision margins in 13 dogs (27.1%). The median
DFI recorded was 196 days (range 30–992 days)
and the median OS was 258 days (range 70–992
days). Five censored cases were included in this
study: two died for unrelated causes (euthanasia for
orthopedical problems in one dog and ab ingestis
pneumonia caused by idiopathic megaesophagus in
the second dog) while three dogs were still alive at
the end of the monitoring period.
Histopathology
Histopathology revealed that 30/48 cases (62.5%)
of CMMs were characterized by the presence
of melanin, while 18/48 (37.5%) were amelan-
otic. Regarding the histotype, 14 CMM were
spindle-shaped (29.2%), 12 epithelioid (25%) and
22 mixed (45.8%).
IHC analysis
All samples analysed showed positivity to PNL-2
antigen, confirming the diagnosis of melanoma.4
Positivity for Ki67 was <19.5% in 16 cases (33.3%)
and >19.5% in 32 cases (66.7%).
Immunolabelling for both PDGFR-𝛼 and -𝛽
receptors was observed at cytoplasmic level and dif-
fusely within the tumour (Figs. 1 and 2). PDGFR-𝛼
and 𝛽 expression was observed in 26/48 (54.2%)
cases and 23/48 (47.9%), respectively. Among the
48 cases analysed, 15 (31.2%) were negative for
both the PDGF receptors, 18 samples (37.5%) were
positive to both PDGFR-𝛼 and -𝛽, 8 (16.7%) were
positive to PDGFR-𝛼 and negative to PDGFR-𝛽,
while seven (14.6%) were positive to PDGFR-𝛽
only. Regarding the positivity in the stromal cells
compartment, PDGFR-𝛼 was present in 13/48
cases (27.1%), PDGFR-𝛽 in 8/48 (16.7%); of those,
5/48 (10.4%) were positive for both receptors.
Statistical analysis
Dogs with oral CMM expressing both PDGFR-𝛼
and -𝛽 had a statistically significant lower DFI
(median 159 days versus 239 days, P< 0.05) and a
lower OS (median 183 days vs. 335 days, P< 0.05)
compared with dogs with CMM not co-expressing
these receptors (Fig. 3). Also, a high Ki67 index
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Figure 1. Malignant melanoma. Neoplastic cells with a
diffuse and strong cytoplasmic immunolabelling for PDGFR
𝛼 (purple staining) streptavidin–biotin–peroxidase method.
Mayer’s haematoxylin counterstaining. Scale bar: 50 μM.
C
ol
or
Figure 2. Malignant melanoma. Neoplastic cells with a
diffuse and strong cytoplasmic immunolabelling for PDGFR
𝛽 (purple staining) streptavidin–biotin–peroxidase method.
Mayer’s haematoxylin counterstaining. Scale bar: 50 μM.
was statistically associated with both a shorter DFI
(188 days versus 484 days – P< 0.05) and a shorter
OS (median 224 days versus 484 days – P< 0.05)
(Fig. 4). The number of the samples available didAQ5
not allow the evaluation of the prognostic value
of the single expression of PDGFR-𝛼 or -𝛽. How-
ever, the expression of PDGFR-𝛼 was statistically
associated with the expression of PDGFR-𝛽 (Chi
square test, P< 0.05). Other evaluations comparing
the IHC results with all the clinical or pathological
data available did not show any statistical associ-
ation. Besides, in this series of cases, no statistical
differences in survival were found comparing
patients of different clinical stage or those with
complete and incomplete surgical excision. The
Cox regression model for proportional hazard
assessment of PDGFR co-expression in interaction
with high values of Ki67 was statistically significant
(P< 0.05) and yielded odds ratio of 1.65 for the
co-expression and 1.96 for the Ki67, respectively
(R2 = 0.159, log-rank test P< 0.05). However, the
confidence intervals for the coefficients were quite
wide owing to the limited sample size (0.77–3.57
for co-expression and 0.78–4.81 for Ki67).
Discussion
CMM is the most common oral malignancy in
dogs and is generally locally aggressive and highly
metastatic. Primary tumour en bloc resection and
regional lymphadenectomy, with or without adju-
vant radiotherapy, are the preferred methods of
treatment and results in loco-regional control in
up to 75% of CMMs. Disappointingly, the 1-year
survival rate is less than 30%, even after adju-
vant treatment; in particular, adjuvant chemother-
apy does not result in a significant increase of the
disease-free period.26–28 It may also be argued that
the post-surgical outcome may be influenced by
the clinical stage, but the authors of this paper did
not reach any conclusion from the present data.29
Immunotherapy against specific tumour associated
antigens30 has been employed in an adjuvant setting
in an attempt to improve the life expectancy in case
of CMM and results appear encouraging.31,32
PDGFRs are physiologically expressed in a
variety of cell types, such as fibroblasts, vascu-
lar smooth muscle cells and endothelial cells,10
suggesting a role also in the interaction between
neoplastic cells and stromal compartment during
tumour progression and invasion.29 PDGFR-𝛼
and -𝛽 receptors are activated by specific solu-
ble factors known as PDGF-A and -B that act as
dimeric isoforms (PDGF-AA, -AB, and -BB) as
well as the newly discovered protease activated
isoforms PDGF-C and PDGF-D. PDGF-AA binds
selectively to PDGFR-𝛼, while PDGF-B chain
isoforms bind and dimerize both PDGFR-𝛼 and
PDGFR-𝛽. In humans, several studies demon-
strated the ability of PDGF ligands to interact with
PDGFR-𝛼 and -𝛽 and induce homodimerization
and/or heterodimerization of the receptors.33,34
As shown previously, in our samples we found
that the co-expression of both isoforms was higher
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Figure 3. Kaplan–Meier curve of DFI (left box) in patients with melanoma co-expressing both PDGFR-𝛼 and -𝛽 (median AQ6
159 days) and not co-expressing PDGFR-𝛼 and -𝛽 (median 239 days – log-rank test: P< 0.05) and Kaplan–Meier curve of
OS (right box) in patient co-expressing both PDGFR-𝛼 and -𝛽 (median 183 days) and not co-expressing PDGFR-𝛼 and -𝛽
(median 335 days – log-rank test: P< 0.05).
Figure 4. Kaplan–Meier curve of DFI (left box) in patient with Ki67> 19.5% (median 188) and Ki67< 19.5% (median
484 – log-rank test: P> 0.05) and Kaplan–Meier curve of OS (right box) in patient with melanoma positive (median 224
days) and negative for PDGFR-𝛼 (median 484 days – log-rank test: P< 0.05).
(37.5%) than the presence of PDGFR-𝛼 or -𝛽
alone (16.7 and 14.6%, respectively). This finding
may suggest that these receptors can act inde-
pendently by homodimerization as well as by
heterodimerization.35
A study on PDGFs and PDGFRs in human cuta-
neous melanomas36 demonstrated that, at IHC,
both the primary and metastatic melanoma exhib-
ited significant expression of PDGF-AA, PDGF-BB
and PDGF-𝛼 receptor when compared with nor-
mal skin, while no expression for PDGF-𝛽 receptor
was recorded. These results have been recently
confirmed by a study where PDGFR-𝛼 resulted
overexpressed in a small population of human
melanomas (4.6%) and an increased copy number
was found.37–40 Contrary to human melanoma,
in our sample PDGFR-𝛽 was expressed in 37.5%
of samples, thus suggesting a different role. In the
present study, PDGFRs were detected not only in
tumour tissue but also in the stromal compartment,
suggesting a potential role in matrix remodelling
and tumour invasion.12
In domestic animal tumours, the IHC expres-
sion of PDGFRs has been investigated in
astrocytoma,19 lymphoma,17 osteosarcoma,16
anal sac adenocarcinoma,18 thyroid carcinoma41
and haemangiosarcoma,20 highlighting the impor-
tance of these receptors also in the tumour biology
of animals, as it occurs in humans.42 However, for
none of these tumours a prognostic relevance has
been demonstrated.
One important limitation of this study is its retro-
spective nature. Nevertheless, results show that the
co-expression of PDGFR-𝛼 and PDGFR-𝛽 (37.5%
of all CMMs of this series) is statistically associated
to both DFI and OS (P< 0.05) and could therefore
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be considered as a negative prognostic factor. This
study also confirms the prognostic importance of
Ki67,24 whereas results regarding free versus infil-
trated surgical margins, in the face of an en bloc
surgery (CMM considered inoperable, i.e. with no
chance to get clean margins at surgery, were not
included here), and clinical stage failed to corre-
late with survival. Although this is an unexpected
result, it should be considered that, as shown in
another study dealingwith a greater number of dogs
with CMM, other factors such as the old age of
the dogs and the size of the tumour may act as
negative prognosticators.27 It should also be noted
that, in this study, no stage I CMMs was included
and only stage II and III CMM were considered.
Collectively, the data obtained from this study sug-
gest that PDGFRs may play a role in the patho-
genesis of CMM and the co-expression of both
PDGFRs-𝛼 and -𝛽 should be taken in account as
a negative prognostic marker. Further prospective
studies on a greater number of cases are warranted
to confirm this finding.
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